Abstract:Andres Morales Corado ^ Division of Clinical Genetics, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, USA ^ ORCID: 0000-0002-2987-4567. Comment on: Li M, Chen X, Chen H, et al . Genetic background and clinical characteristics of infantile hyperammonemia. Transl Pediatr 2023;12:882-9. Keywords: Hyperammonemia; inborn errors of metabolism (IEM); citrin deficiency; SLC25A13; management Submitted Dec 08, 2023. Accepted for publication Jan 03, 2024. Published online Feb 26, 2024. doi: 10.21037/tp-23-593 Hyperammonemia is an accumulation of ammonia, a nitrogen compound, resulting from protein catabolism, either by intestinal bacteria, or by muscle proteins in the presence of reduced energy sources (1,2). Following its production, ammonia is then coupled with glutamate for glutamine synthesis and later used by hepatic metabolism (urea cycle) to convert it into urea and subsequent excretion by the kidney (3). With multiple situations that could lead to hyperammonemia in infants and newborns, there is no final consensus on what constitutes normal ammonia values thus far. Commonly used cutoffs are below (healthy) and above (sick) 100 μmol/L (4,5). Hyperammonemia etiologies have been divided into three groups (4,6,7): Most etiologies within the primary and secondary causes of hyperammonemia correspond to a larger group of conditions known as inherited metabolic disorders (IMD) or inborn errors of metabolism (IEM) (8). These group of disorders could be fatal if not promptly identified. The symptomatology of hyperammonemia, regardless of etiology, is non-specific. Symptoms such as decreased appetite, dyspnea, hypothermia, lethargy, seizures and ultimately coma (due to cerebral edema) could be seen in most if not all the conditions (according to severity) listed above (8). Therefore, proper diagnostic work-up (blood-urine cultures, cerebrospinal fluid (CSF) analysis, liver synthetic function tests, renal function tests and metabolic tests e.g., plasma acylcarnitines, plasma amino acids, urine organic acids) is essential towards specific and more efficient management (6,9). As confirmed by Li et al. the most common genetic disorders leading to hyperammonemia in their cohort were cholestasis related disorders, urea cycle disorders and organic acidemias (10). The latter two groups are often linked, as organic acids are regulators of essential enzymes such as N-acetylglutamate synthase (11). Another interesting detail is that their most common single gene etiology was citrullinemia type 2/citrin deficiency ( SLC25A13 ) a condition that some researchers classify as urea cycle disorder while some others consider it primarily a cholestasis/liver disorder that collaborates with the cycle (12). Citrullinemia type 2 has a large prevalence in Japan, but in the past few years, other East Asian populations like China, have demonstrated a higher prevalence as well, which is further confirmed by Li et al. (13,14). Li et al. further solidified that IEMs known to cause hyperammonemia continue to be the most frequent genetic etiologies for this situation. And while they were able to identify other genes not previously associated to hyperammonemia, such as JAG1, one must be careful upon correlating these data, as there could have been other confounding factors not previously recorded; a limitation clearly stated by the authors. The impact of understanding the presentation and prevalence of these hyperammonemia related IEMs lies on timely diagnosis. While hyperammonemia could be fairly controlled with either high caloric intake (either through intravenous fluids or orally), nitrogen scavengers (such as sodium benzoate or glycerol phenylbutyrate) or ultimately by continuous renal replacement therapy; there is a high recurrence risk as the main trigger (which in some cases could just be a large meal) has not been identified nor managed (6). And as we are turning into a rare disease therapeutics era that not only involves organ transplantation for IEMs, but also mRNA and gene therapy, knowing the most relevant details of these conditions will become paramount for their care (15-18). Funding: None. Provenance and Peer Review: This article was commissioned by the editorial office, Translational Pediatrics . The article did not undergo external peer review. Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-23-593/coif). The author has no conflicts of interest to declare. Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Open Access Statement: This is -Abstract Truncated-

Hyperornithinemia, Hyperammonemia, and Homocitrullinuria Syndrome Causing Severe Neonatal Hyperammonemia

Studies on a Case of HHH-Syndrome (Hyperammonemia, Hyperornithinemia, Homocitrullinuria)

Late onset hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome, presenting as recurrent metabolic encephalopathy, A case report

Long-term follow-up of four patients affected by HHH syndrome

Neonatal form of the hyperornithinaemia, hyperammonaemia, and homocitrullinuria (HHH) syndrome and prenatal diagnosis

HHH syndrome (hyperornithinaemia, hyperammonaemia, homocitrullinuria), with fulminant hepatitis-like presentation

Diagnosis and high incidence of hyperornithinemia-hyperammonemia-homocitrullinemia (HHH) syndrome in northern Saskatchewan

Prenatal exclusion of the hhh syndrome

Identification of novel mutations in the SLC25A15 gene in hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome: A clinical, molecular, and functional study

Hyperornithinemia-hyperammonemia-homocitrullinuria: a rare neurometabolic disorder in two siblings

Biochemical Analysis of Decreased Ornithine Transport Activity in the Liver Mitochondria from Patients with Hyperornithinemia, Hyperammonemia and Homocitrullinuria.

Ornithine In Vivo Administration Disrupts Redox Homeostasis and Decreases Synaptic Na+, K+-ATPase Activity in Cerebellum of Adolescent Rats: Implications for the Pathogenesis of Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) Syndrome

Corticospinal tract damage in HHH syndrome: a metabolic cause of hereditary spastic paraplegia

A novel mutation in the SLC25A15 gene in a Turkish patient with HHH syndrome: Functional analysis of the mutant protein

Dual mechanism of brain damage induced in vivo by the major metabolites accumulating in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome

Hyperammonemic Encephalopathy in a Child with Ornithine Transcarbamylase Deficiency Due to a Novel Combined Heterozygous Mutations

Clinical and Functional Characterization of a Human ORNT1 Mutation (T32R) in the Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) Syndrome

[Clinical and Laboratory Screening Studies on Urea Cycle Defects].

Neonatal Presentation of Ornithine Transcarbamylase Deficiency Associated With a Hypomorphic OTC Variant (p.Leu301Phe) Previously Reported in Later-Onset Disease

A novel R275X mutation of the SLC25A15 gene in a Japanese patient with the HHH syndrome

Hyperammonemia and inborn errors of metabolism